Positive result for Botanix safety test

Trevor Chappell
AAP

Botanix Pharmaceuticals has successfully completed a safety trial of its Permetrex drug delivery formulation, which the skin diseases treatment developer says will enable further tests of dermatological products containing synthetic cannabidiol.

Botanix said on Wednesday it has successfully completed the first human testing of its Permetrex skin drug delivery formulation, which showed no safety issues and minimal or weak irritancy potential.

Botanix will now proceed to a study that combines the Permetrex formulation with Botanix's BTX-1503 formulation, which includes the synthetic cannabidiol - the natural form of which is contained within marijuana.

"Permetrex showed very low potential to irritate the skin which means we can proceed with confidence into the next study for BTX-1503 including synthetic cannabidiol in the formulation," said Botanix executive director Matt Callahan.

Mr Callahan said the ability to drive drugs more efficiently into the skin, without the risk of serious irritation and other safety concerns from the delivery technology, opens up new opportunities for Botanix across a wide range of diseases.

Shares in Botanix were 0.2 cents lower at 4.8 cents at 1254 AEDT.